NanOlogy

NEWS

Business

Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

November 6, 2018

·

12 min read

·

IN THE PRESS

Drug Development

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

December 19, 2023

·

3 min read

Drug Development

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer

October 10, 2023

·

6 min read

Lone Star Bio

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

June 7, 2023

·

3 min read

Lone Star Bio

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

March 7, 2023

·

4 min read

Lone Star Bio

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

December 20, 2022

·

3 min read

Drug Development

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

November 11, 2022

·

3 min read

Drug Development

CORRECTING and REPLACING NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX

October 3, 2022

·

3 min read

Drug Development

NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX

September 20, 2022

·

3 min read

Drug Development

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

August 1, 2022

·

5 min read

Drug Development

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

May 3, 2022

·

4 min read

AWARDS

JOBS